India Globalization Capital, Inc.: directors' dealings · United States · SEC (Form 4)

About India Globalization Capital, Inc.

India Globalization Capital, Inc. is a U.S.-listed company trading on NYSE American, part of the NYSE family of markets, and is incorporated in Maryland, United States. Founded in 2005, the company has undergone a notable strategic evolution: it was originally conceived as a vehicle for business combination and infrastructure-related activities with an India focus, but in recent years it has increasingly repositioned itself toward life sciences and biotechnology. In its most recent SEC filing, the company states that it now operates as a single reportable segment focused on its mission to help make the world free from Alzheimer’s. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/igc10k033125.htm)) The company’s headquarters are in Potomac, Maryland. It also maintains offices and/or operating presence in Washington state, Colombia, and India, and it owns or leases facilities used for general management, R&D, manufacturing, sales, and distribution. This footprint suggests a relatively compact operating platform, consistent with a development-stage small-cap company rather than a fully scaled commercial healthcare group. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/igc10k033125.htm)) Today, the core investment case centers on IGC Pharma and its Alzheimer’s pipeline. The lead candidate, IGC-AD1, is being developed for agitation in Alzheimer’s dementia, a symptom area the company describes as a major unmet medical need. Management has highlighted positive interim Phase 2 updates in 2024 and a clinical study presentation dated June 2025. While the strategic emphasis is now clearly life sciences, the company still references ancillary revenue streams from wellness and lifestyle products, white-label services, and legacy infrastructure-related activities such as equipment rental and contract execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/igc10k033125.htm)) From a competitive standpoint, IGC should be viewed as a high-risk, high-upside clinical development story rather than a mature commercial pharmaceutical company. Its market position is driven less by scale and more by pipeline differentiation, regulatory progress, and capital access. The company’s recent filings show limited revenues and a constrained balance sheet, which is typical of a micro-cap biotech funding drug development. For investors in France, Belgium, and Switzerland, the relevant lens is execution risk: clinical readouts, financing capacity, and eventual regulatory traction will matter far more than near-term sales momentum. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1326205/000118518526000941/igc10kt123125.htm?utm_source=openai)) Recent company developments underscore that shift. In fiscal 2025, IGC reassessed its reporting structure in connection with its strategic realignment toward life sciences, stated that the infrastructure segment no longer generated revenue and was no longer actively managed as a separate operating segment, and continued advancing IGC-AD1. SEC disclosures also confirm the company’s NYSE American listing and ongoing governance and financing activity typical of a publicly traded development-stage issuer. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/igc10k033125.htm))